These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38925680)

  • 1. Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies.
    Zhang W; Chen X; Chen X; Li J; Wang H; Yan X; Zha H; Ma X; Zhao C; Su M; Hong L; Li P; Ling Y; Zhao W; Xia Y; Li B; Zheng T; Gu J
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy.
    Wang H; Xu Q; Zhao C; Zhu Z; Zhu X; Zhou J; Zhang S; Yang T; Zhang B; Li J; Yan M; Liu R; Ma C; Quan Y; Zhang Y; Zhang W; Geng Y; Chen C; Chen S; Liu D; Chen Y; Tian D; Su M; Chen X; Gu J
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
    Huang Z; Pang X; Zhong T; Qu T; Chen N; Ma S; He X; Xia D; Wang M; Xia M; Li B
    Front Immunol; 2022; 13():924542. PubMed ID: 35833116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction.
    Mostböck S; Wu HH; Fenn T; Riegler B; Strahlhofer S; Huang Y; Hansen G; Kroe-Barrett R; Tirapu I; Vogt AB
    Front Immunol; 2022; 13():862757. PubMed ID: 35967294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
    Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
    MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
    Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
    Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q; Lajoie L; Barrault B; Thibault G
    Front Immunol; 2020; 11():168. PubMed ID: 32117299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform.
    Kang CE; Lee S; Ahn T; Seo DH; Ko BJ; Jung M; Lee J; Kim JY; Kim WT
    Sci Rep; 2022 Nov; 12(1):19030. PubMed ID: 36347901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant thyroid peroxidase-specific Fab converted to immunoglobulin G (IgG) molecules: evidence for thyroid cell damage by IgG1, but not IgG4, autoantibodies.
    Guo J; Jaume JC; Rapoport B; McLachlan SM
    J Clin Endocrinol Metab; 1997 Mar; 82(3):925-31. PubMed ID: 9062508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions.
    Rispens T; Ooievaar-De Heer P; Vermeulen E; Schuurman J; van der Neut Kolfschoten M; Aalberse RC
    J Immunol; 2009 Apr; 182(7):4275-81. PubMed ID: 19299726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy.
    Zhang W; Quan Y; Ma X; Zeng L; Li J; Chen S; Su M; Hong L; Li P; Wang H; Xu Q; Zhao C; Zhu X; Geng Y; Yan X; Fang Z; Chen M; Tian D; Su M; Chen X; Gu J
    Redox Biol; 2023 Apr; 60():102608. PubMed ID: 36681047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of deglycosylated human IgG4-Fc.
    Davies AM; Jefferis R; Sutton BJ
    Mol Immunol; 2014 Nov; 62(1):46-53. PubMed ID: 24956411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid-induced aggregation propensity of nivolumab is dependent on the Fc.
    Liu B; Guo H; Xu J; Qin T; Xu L; Zhang J; Guo Q; Zhang D; Qian W; Li B; Dai J; Hou S; Guo Y; Wang H
    MAbs; 2016; 8(6):1107-17. PubMed ID: 27310175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.
    Gordeev A; Vaal A; Puchkova M; Smirnova I; Doronin A; Znobishcheva A; Zhmudanova D; Aleksandrov A; Sukchev M; Imyanitov E; Solovyev V; Iakovlev P
    Sci Rep; 2024 Oct; 14(1):23136. PubMed ID: 39367001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
    Zhang T; Song X; Xu L; Ma J; Zhang Y; Gong W; Zhang Y; Zhou X; Wang Z; Wang Y; Shi Y; Bai H; Liu N; Yang X; Cui X; Cao Y; Liu Q; Song J; Li Y; Tang Z; Guo M; Wang L; Li K
    Cancer Immunol Immunother; 2018 Jul; 67(7):1079-1090. PubMed ID: 29687231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.